Compare TNET & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | WGS |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2000 | 2020 |
| Metric | TNET | WGS |
|---|---|---|
| Price | $69.25 | $94.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $65.80 | ★ $120.71 |
| AVG Volume (30 Days) | 299.0K | ★ 434.4K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ 3.05 | N/A |
| Revenue | ★ $5,010,000,000.00 | $427,539,000.00 |
| Revenue This Year | N/A | $29.98 |
| Revenue Next Year | $3.30 | $25.92 |
| P/E Ratio | $21.64 | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $33.67 | $32.21 |
| 52 Week High | $73.08 | $170.87 |
| Indicator | TNET | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 64.93 |
| Support Level | $64.80 | $81.37 |
| Resistance Level | $72.19 | $94.82 |
| Average True Range (ATR) | 2.28 | 4.23 |
| MACD | -0.57 | -0.58 |
| Stochastic Oscillator | 57.92 | 80.74 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.